



23 July 2019

BAPEN response: Patients dependent on home parenteral nutrition are experiencing delays in vital deliveries due to MHRA restrictions placed on Calea UK

An urgent and concerning issue regarding the immediate welfare and safety of patients requiring Home Parenteral Nutrition (HPN) has recently been brought to BAPEN's attention.

Following a recent inspection by the Medicines and Healthcare products Regulatory Authority (MHRA) of Fresenius Kabi Calea's site in Runcorn, it was identified that there was an urgent need to change some aspects of its manufacturing process in order to meet current MHRA safety guidance. Although there is no evidence of defective products on the market, FK Calea has needed to reduce its production output while it makes these changes. This means that crucial intravenous nutritional solutions and fluids are not being delivered to all high-risk patients in the UK.

There are approximately 2,500 adults and children receiving HPN in the UK and the current problem with Calea's production processes is affecting a lot of patients and impacting upon NHS services while nutrition teams seek to support patients and emergency hospitalisations are managed. BAPEN is working closely with other organisations to offer support and counsel to FK Calea and the Department of Health and Social Care (DHSC) while a solution to this issue is sought.

If you are a patient concerned about your HPN supply or delivery, please contact your HPN centre directly, or if you do not feel able to speak to them directly, via the Patient and Advisory Liaison Service (PALS) of the hospital. Details of this service will be available on the internet.

Following this, if you feel that your issue still remains unresolved, you can also contact the [Parliamentary and Health Service Ombudsman](#) on 0345 015 4033.

For any questions directly for BAPEN, we can be contacted at bapen@bapen.org.uk.